Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Influenza A virus wikipedia , lookup
Canine distemper wikipedia , lookup
Canine parvovirus wikipedia , lookup
Marburg virus disease wikipedia , lookup
Hepatitis C wikipedia , lookup
Human cytomegalovirus wikipedia , lookup
Henipavirus wikipedia , lookup
Hepatitis B wikipedia , lookup
Seattle/Kenya Collaboration- MTCT Julie Overbaugh Collaborating Institutions: University of Nairobi Fred Hutchinson Cancer Research Center University of Washington Designing an effective vaccine: -> Identifying immune correlates • A major focus of HIV vaccine efforts is trying to elicit HIVspecific NAbs. • Most successful vaccines are thought to work through antibody-mediated protection. • Do NAbs protect against HIV? Antibody Target cell (e.g. T Cell) NAbs can block HIV (SHIV) infection in macaques Virus levels Controls Given HIV NAb (HIVIG/2F5/2G12) (Mascola et al. Nat. Med. 2000) • High levels of antibodies were used, much higher than in HIV infection. • Challenge dose was high • Antibody was matched to the virus (SHIV89.6PD), but would not have ‘matched’ most viruses in the ‘real world’ There is surprisingly little evidence that NAbs contribute to protection from HIV in humans Easy to neutraliz e Hard to neutraliz e Neutralization sensitivity HIV is both genetically and antigenically diverse •At any given time, most people harbor a mixture of neutralization sensitive and neutralization resistant viruses due to the dynamic process of immune escape. Studies of HIV-exposed cohorts: MTCT MTCT MTCT occurs in the presence of a HIV-specific NAb response in the mother. HIV-specific NAbs are present in the infant due to passive transfer, especially near the time of delivery and during breastfeeding Nairobi breastfeeding clinical trial 1992-1998: Ruth Nduati Joan Kreiss University of Nairobi University of Washington • Randomized clinical trial comparing infant HIV-1 infection between breast-fed and formula-fed groups (N=425) to determine the frequency and timing of breast milk HIV-1 transmission from a mother to her infant. • In 1992: Risk was unclear and ARVs were not available. Dorothy Mbori-Ngacha Grace John-Stewart Barb Richardson Nairobi Breastfeeding Clinical Trial (1992-1998) Breast feeding doubles the risk of infant infection The majority of breastfeeding transmission occurs in the first 6 weeks postpartum % infected 40% 6 months 14 wks 12 months 24 months 30% 6 wks 20% 10% 0% Child age HIV Infection rate-Breastfeeding HIV Infection rate-Formula feeding Nduati, et al. Effect of Breastfeeding and Formula Feeding on Transmission of HIV-1. JAMA 2000:283:1167-1174 ~ Sixty % of infants do not get infected despite exposure in utero, intrapartum and through breastfeeding Do NAb contribute to protection? 100% 80% uninfected 60% 40% 20% 0% Do NAb play a role in protection of infants? 100% Select 100 infants in the breastfeeding arm who were HIV negative at birth 80% N=68 60% 40% 20% N=32 0% Examine the breadth of the NAb response near delivery: mom and baby Hypothesis: NAb contribute to protection If a broad and potent NAb response provides protection, then these infants are less likely to be infected To measure breadth and potency of the NAb response, we use a panel of circulating HIV variants • Variants from early in infection representing circulating viruses Plasma RNA Hard to neutraliz e • A range of NAb sensitivities Neutralization sensitivity Easy to neutraliz e This heterologous panel gives a measure or breadth and potency of the NAb response Neutralization is quantified by determining IC50 values IC50s were determined for each virus/plasma combination Virus 1 IC50 = 620 Virus 2 IC50 <100 1:100 1:200 1:400 1:800 1:1600 1:3200 Plasma dilution IC50s are defined as the reciprocal dilution of plasma or MAb required to inhibit infection by 50% (based on the dose response curve, log function). Higher IC50 means more potent neutralization 100 infant plasma at birth IC50 Lynch et al. J. Virol. 2011 10 9 6 40 3 14 8 20 55 There was no difference in the breadth or potency of HIV NAb in infants who became infected versus those who remained uninfected Lynch et al., JV 2011 Similar results were obtained when we examined the breadth of the maternal Nab response in relation to infant infection. Majiwa, submitted. J. Lynch M. Majiwa Do NAbs protect against the most neutralization sensitive viruses? 100% 80% 60% 40% 20% 0% } Infected Isolate maternal and infant envelope variants and test neutralization sensitivity (N= 12 pairs, 96 envs) Mom virus (week 0) Baby virus (week 6) NAbS NAbR? NAbR Maternal antibodies (wk 0) Infant viruses variants are poorly neutralized by maternal NAbs. IC50 values versus autologous Ab near the time of infection Neutralization sensitivity p=0.02 Viruses neutralized by maternal plasma 1000 100 No detectable neutralization 10 Transmitting mothers X. Wu Infected infants Wu, JV, 2006 IC50 values versus autologous Ab near the time of infection Neutralization sensitivity Infant viruses variants are poorly neutralized by maternal NAbs. Sensitive variants are not transmitted 1000 Wu, JV 2006 100 10 Transmitting mothers Infected infants Nab elicited by HIV infection may have adequate potency to block the most neutralization sensitive variants Easy to neutraliz e Ab needed to neutralize 1000 100 10 Hard to neutraliz e Transmitting mothers Infected infants How does this fit with the first study, showing a lack of association between breadth and potency and risk of infant infection? Ab needed to neutralize A broad and potent Nab response per se does not correlate with transmission because the mothers harbor a mix of neutralization sensitive and resistant viruses and the Nab are only able to get the ‘low hanging fruit” Mom’s virus NAbs can block HIV (SHIV) infection in macaques Virus levels Controls Given HIV NAb (HIVIG/2F5/2G12) (Mascola et al. Nat. Med. 2000) • Antibody was matched to the virus (SHIV89.6PD), which was a very neutralization sensitive virus. These data suggest together with animal model studies, suggest that Nab perhaps can protect against the more neutralization sensitive viruses > The Nab breadth/potency needed for protection remains unclear Easy to neutraliz Current e SHIVs Ab needed to neutralize 1000 100 10 Hard to neutraliz e Transmitting mothers Infected infants Perhaps the protective antibodies are acting locally, e.g. in breast milk to reduce infectiousness? Courtesy, Grace John-Stewart Breastmilk NAbs are low • • Mabuka, J et.al PloS Path 2012 Low level neutralizing activity is detected in BMS, but much of this is non-specific. NAbs are only rarely detected in purified antibody fractions (IgG, IgA). J. Mabuka Transmitting mothers have higher levels of cell-associated breast milk HIV than non transmitting mothers. (Log10 BM cell DNA/106 cells) Cell-associated BM levels Non transmitting Rousseau, JID 2004 Cell-free virus RNA form Transmitting Adjusted 1.11 p =0.002 1.67 Infected cell Cell-associated virus DNA form C. Rousseau Antibody neutralization ADCC : Antibody-dependent cell cytotoxicity Prevents new rounds of infection Leads to elimination of infected cells Effector cell Fc Receptor (e.g. NK cell) granzymes, perforin Target cell (e.g. T Cell) Infected cell ADCC assay measures killing of HIV coated cells in the presence of Ab. CFSE PKH-26 + HIV Envelope protein Effector cell (PBMCs + (subtype A) BM Abs Target cell (CEM.NKr cells) BMS 1:100 96 42.8 57.2 PKH-26 4.0 Uncoated Target cells Envelope Coated Target cells CFSE *ADCC % Killing= %PKH+ cells, CFSE- cells - 2x background Breast Milk ADCC is correlated with risk of infant infection p =0.039 Non transmitting Mabuka, J et.al PloS Path 2012 Transmitting J. Mabuka Take home • NAb can protect against highly sensitive variants in MTCT, but the amount needed and the breadth to achieve a protective Nab responses is unclear. • Suggest the breadth and potency needed to protect against diverse HIV variants circulating globally is likely higher than elicited by chronic Hiv infection. • Antibodies that act through ADCC may contribute to protection, especially in settings where cell-associated virus is contributing to transmission.